Drugs /
berzosertib
Overview
Clinical Trials
Berzosertib has been investigated in 21 clinical trials, of which 18 are open and 3 are closed. Of the trials investigating berzosertib, 8 are phase 1 (6 open), 5 are phase 1/phase 2 (5 open), and 8 are phase 2 (7 open).
ATM Loss, ATM Mutation, and ATR Loss are the most frequent biomarker inclusion criteria for berzosertib clinical trials.
Malignant solid tumor, small cell lung carcinoma, and non-small cell lung carcinoma are the most common diseases being investigated in berzosertib clinical trials [2].
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].
2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.